|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600123017 |
|
最近更新日期: Date of Last Refreshed on: |
2026-04-21 08:42:47 |
|
注册时间: Date of Registration: |
2026-04-21 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
卒中后重度上肢偏瘫的跨半球代偿研究 |
|
Public title: |
Study on Cross-Hemispheric Compensation in Severe Upper Limb Hemiplegia After Stroke |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
卒中后重度上肢运动障碍跨半球代偿模式及机制的循证研究 |
|
Scientific title: |
Evidence-Based Study on the Cross-Hemispheric Compensation Patterns and Mechanisms in Severe Upper Limb Motor Dysfunction After Stroke |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
李冉 |
研究负责人: |
李冉 |
|
Applicant: |
Ran Li |
Study leader: |
Ran Li |
|
申请注册联系人电话: Applicant telephone: |
+86 10 88062907 |
研究负责人电话: Study leader's telephone: |
+86 10 8806 2907 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
liran817@sina.com |
研究负责人电子邮件: Study leader's E-mail: |
liran817@sina.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市西城区复兴门外大街甲20号 |
研究负责人通讯地址: |
北京市西城区复兴门外大街甲20号 |
|
Applicant address: |
20#, Fuxingmenwai Street, Xicheng District, Beijing |
Study leader's address: |
20#, Fuxingmenwai Street, Xicheng District, Beijing |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
首都医科大学附属复兴医院 |
||
|
Applicant's institution: |
Fuxing Hospital, Capital Medical University |
||
|
研究负责人所在单位: |
首都医科大学附属复兴医院 |
||
|
Affiliation of the Leader: |
Fuxing Hospital, Capital Medical University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2026FXHEC-KY003 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
首都医科大学附属复兴医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Fu Xing Hospital, Capital Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-02-04 00:00:00 |
||
|
伦理委员会联系人: |
刘群 |
||
|
Contact Name of the ethic committee: |
Liu Qun |
||
|
伦理委员会联系地址: |
北京市西城区复兴门外大街甲20号 |
||
|
Contact Address of the ethic committee: |
20#, Fuxingmenwai Street, Xicheng District, Beijing |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 10 88062032 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
fxyykjc2014@sina.com |
|
研究实施负责(组长)单位: |
首都医科大学附属复兴医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Fuxing Hospital, Capital Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市西城区复兴门外大街甲20号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
20#, Fuxingmenwai Street, Xicheng District, Beijing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
2025年“高创计划·春蕾”项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
Beijing High-level Innovation and Entrepreneurship Talent Support Program · Chunlei Project |
||||||||||||||||||||||
|
Target disease: |
Severe Upper Limb Hemiplegia After Stroke |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
主要研究目的: 本项目旨在通过系统探究卒中后重度上肢运动功能障碍患者健侧半球的跨半球代偿模式及机制,解决当前神经调控技术以患侧半球为靶点的疗效瓶颈这一关键临床问题。 次要研究目的 探索影响跨半球代偿效率的临床因素。 |
||||||||||||||||||||||
|
Objectives of Study: |
Primary Research Objective: This project aims to systematically investigate the interhemispheric compensation patterns and mechanisms of the unaffected hemisphere in patients with severe post-stroke upper limb motor dysfunction, addressing the critical clinical issue of the efficacy bottleneck of current neuromodulation techniques targeting the affected hemisphere. Secondary Research Objective: To explore the clinical factors that influence the efficiency of interhemispheric compensation. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.诊断符合1995年全国第四届脑血管病学术会议通过的各类脑血管病诊断要点,经CT或MRI证实为皮层下卒中; 2.首次发病且单侧发病,病情稳定; 3.2周≤病程≤6月;18岁≤年龄≤80岁; 4.伴有重度上肢运动功能障碍、且患侧上肢布氏分期2-3期(至少有部分肩部主动运动); 5.签署知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Diagnosis meets the key diagnostic points for various cerebrovascular diseases passed at the 1995 National Fourth Cerebrovascular Disease Academic Conference, and subcortical stroke is confirmed by CT or MRI; 2. First onset and unilateral occurrence, with stable condition; 3. Disease duration between 2 weeks and 6 months; age between 18 and 80 years; 4. Accompanied by severe upper limb motor dysfunction, and Brunnstrom stage 2-3 of the affected upper limb (at least partial active shoulder movement); 5. Signed informed consent form. |
||||||||||||||||||||||
|
排除标准: |
1.合并明显患侧上肢肌张力升高(Ashworth分级≥2级); 2.合并明显关节挛缩、肩手综合征、肩痛等并发症; 3.合并严重的肢体深浅感觉障碍; 4.合并严重视空间忽略、倾斜综合征等认知障碍; 5.合并颅内感染、多系统萎缩、卒中后抑郁等其他神经精神类疾病; 6.体内金属植入物; 7.幽闭恐惧症; 8.既往癫痫病史; 9.其他研究者认为不适合参加本临床研究的情况。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Combined with obvious increased muscle tone in the affected upper limb (Ashworth grade ≥ 2); 2. Combined with obvious joint contracture, shoulder-hand syndrome, shoulder pain, and other complications; 3. Combined with severe deep or superficial sensory impairment of the limbs; 4. Combined with severe cognitive impairments such as visuospatial neglect and tilt syndrome; 5. Combined with intracranial infection, multiple system atrophy, post-stroke depression, and other neuropsychiatric disorders; 6. Presence of metal implants in the body; 7. Claustrophobia; 8. History of epilepsy; 9. Other conditions deemed unsuitable for participation in this clinical study by the researchers. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-12-01 00:00:00至 To 2027-12-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2026-05-06 00:00:00 至 To 2027-03-23 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由研究者通过随机数字表法产生随机数列 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
A random sequence will be generated by the researcher using the random number table method. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
三盲(受试者盲、研究者盲、数据分析者盲) |
|
Blinding: |
The triple-blind design includes Blinding of Subjects,Researchers and Data Analysts. |
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
不共享数据 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Data will not be shared. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
1.病例记录表:病例记录表由专人进行临床数据收集及填写,定期进行电子数据录入。2.数据管理:所有具有可识别特征的患者原始数据仅由项目负责人掌握并进行锁定式保存,而后对数据进行去特征化处理,最大程度保护患者隐私;所有项目相关数据仅供内部学术交流使用。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
1. Case Record Form: The case record forms shall be used for clinical data collection and completion by designated personnel, and electronic data entry shall be conducted regularly.2. Data Management: All original patient data with identifiable characteristics shall be held and stored in a locked manner only by the project leader; subsequently, the data shall be de-identified to protect patients' privacy to the greatest extent. All project-related data shall be used only for internal academic exchanges. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |